Enliven Therapeutics, Inc. (ELVN) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Enliven Therapeutics, Inc. on January 6, 2026. The report discloses significant changes to the composition of the Company's Board of Directors, effective January 7, 2026.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, or liquidity metrics. The only financial data disclosed relates to director compensation and prior consulting fees:
- Prior Consulting Fees: $314,650 paid to Scott Garland for services rendered from January 2024 through his board appointment.
- Prior Equity Vesting: 26,580 stock options vested to Scott Garland during the consulting period.
- New Director Cash Compensation: $40,000 annual retainer plus $10,000 annual fee for Chair of the Nominating Committee.
- New Director Equity Grant: Stock options with a grant date fair value of approximately $650,000.
Material Changes
The filing reports two material changes to the Board of Directors:
- Appointment: Scott Garland was appointed as a Class I Director and Chair of the Nominating and Corporate Governance Committee. His term expires at the 2027 annual meeting.
- Resignation: Andrew Phillips, Ph.D., resigned from the Board, the Audit Committee, and the Nominating Committee. The resignation was not due to any disagreement with the Company regarding operations, policies, or practices.
Outlook, Risks, and Unusual Items
The filing does not provide updated business guidance, outlook, or risk factors. It notes that Mr. Garland's new stock options will vest monthly (1/36th per month) and will fully vest in the event of a Change in Control. The Company has also entered into a standard indemnification agreement with Mr. Garland.
Investor Verification Checklist
- Verify the impact of the Board composition change on the Company's strategic direction and governance.
- Review the attached Press Release (Exhibit 99.1) for additional context on the leadership transition.
- Confirm the total number of outstanding shares and the dilution impact of the new $650,000 equity grant to Mr. Garland.
- Check subsequent filings for the Company's latest financial position, as this 8-K contains no operational financial data.